The European Society of Cardiology (ESC), one of the most prestigious institutions dedicated to advancing cardiovascular science, recently bestowed its highest honor, the ESC Gold Medal, upon Dr. Roxana Mehran. This distinguished recognition was awarded during an eminent ceremony held at the ESC Congress in Madrid on August 29, 2025. Dr. Mehran’s accolade is a testament to her groundbreaking contributions in interventional cardiology and clinical cardiovascular research, areas that continually redefine patient care paradigms worldwide.
Dr. Mehran, serving as Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai, has been a pivotal figure in the global cardiology community. Her work primarily focuses on devising novel randomized clinical trials and outcome research frameworks that ensure high standards of evidence-based practice. Her scientific influence extends through her prolific authorship of over 2,000 peer-reviewed articles, influencing clinical guidelines and therapeutic strategies for acute and chronic cardiovascular conditions.
One of the technical hallmarks of Dr. Mehran’s research resides in personalized cardiovascular medicine. She has been instrumental in developing validated individual risk scores that predict the probability of procedural complications such as bleeding and acute kidney injury. These risk stratification tools represent a vital advancement for tailoring therapeutic interventions to individual patient risk profiles, thereby improving procedural safety and optimizing overall clinical outcomes.
Her research methodology uniquely integrates large-scale, multicenter randomized trials with sophisticated outcome analytics, advancing the understanding of interventional procedures such as percutaneous coronary intervention (PCI). By meticulously examining factors that influence procedural success and patient recovery, her work enables clinicians to refine pre-procedural assessments and post-procedural management, mitigating complications and enhancing long-term cardiovascular health.
Dr. Mehran’s influence transcends individual clinical trials. She has played an essential role in shaping international cardiovascular practice guidelines through her consistent participation in guideline committees. Her contributions have fostered consensus on managing complex cardiovascular diseases, particularly in tailoring interventions based on risk stratification, which has been a foundational paradigm shift toward precision cardiovascular care.
Leadership is a recurring theme in Dr. Mehran’s career. She holds prominent roles including the vice presidency on the Board of Trustees at the American College of Cardiology (ACC) for 2025-2026 and serves as Chief Scientific Officer of the Cardiovascular Research Foundation (CRF). Through these influential platforms, she champions innovative research agendas and fosters collaborative networks that accelerate scientific discovery and clinical translation globally.
In addition to her robust academic and clinical research endeavors, Dr. Mehran has pioneered programs addressing gender disparities in cardiovascular medicine. She leads the Lancet Commission on Women’s Cardiovascular Diseases, an initiative mobilizing global expertise to elucidate sex-specific differences in cardiovascular physiology, disease progression, and therapeutic responses. This work aims to bridge critical knowledge gaps and promote equitable clinical trial representation.
Further advancing women’s cardiovascular health, Dr. Mehran directs the Women’s Heart and Vascular Center at Mount Sinai Fuster Heart Hospital. This center integrates multidisciplinary approaches catering exclusively to female patients’ unique pathophysiological and psychosocial cardiovascular risk factors. This integration exemplifies the transition toward specialized clinical pathways that acknowledge and address sex-specific cardiovascular manifestations.
Among her many accolades, Dr. Mehran has garnered numerous elite awards that signify her extensive impact on cardiology and medical science. Highlights include the 2016 American College of Cardiology’s Bernadine Healy Leadership Award, the 2019 European Society of Cardiology Silver Medal, the 2024 Icahn School of Medicine’s Jacobi Medallion, and notably, the 2025 ESC Gold Medal. These awards reflect both her scientific excellence and leadership in fostering research innovations.
Mount Sinai Health System, home to Dr. Mehran’s distinguished career, ranks among the world’s preeminent centers for cardiovascular care and research. The Mount Sinai Fuster Heart Hospital is nationally acclaimed, positioning second in the United States for cardiology and heart surgery according to U.S. News & World Report, and is recognized globally by Newsweek among the top specialized hospitals. This institutional excellence synergizes with Dr. Mehran’s work, creating an environment conducive to cutting-edge cardiovascular discoveries.
The recognition by the ESC not only celebrates Dr. Mehran’s individual achievements but also elevates the visibility of interventional cardiology’s evolving landscape. Interventional cardiology has rapidly progressed with advancements in device technology, procedural techniques, and perioperative pharmacotherapy, all areas where Dr. Mehran’s research has been influential. Her work has emphasized the seamless fusion of bench research with bedside applications, ensuring that innovative therapies translate into tangible clinical benefits.
This award highlights the pivotal role of mentorship and collaborative science in cardiovascular medicine. Dr. Mehran consistently emphasizes that such honors reflect the collective efforts of diverse teams, including junior investigators, clinical collaborators, and institutional support systems. Her commitment to nurturing the next generation ensures ongoing progress in a field that demands continuous innovation to combat the global burden of cardiovascular diseases.
The cardiovascular research community worldwide acknowledges that addressing the multifaceted challenges of cardiovascular disease requires dynamic leadership and interdisciplinary collaboration. Dr. Mehran’s career exemplifies this holistic approach, integrating clinical insights, methodical research, and advocacy for inclusivity and equity in medicine. The ESC Gold Medal serves as a beacon of scientific rigor, leadership, and dedication to patient-centered innovation in cardiovascular health.
As cardiovascular diseases remain a leading cause of global morbidity and mortality, the scientific contributions of thought leaders like Dr. Mehran are fundamental to improving outcomes. Her pioneering efforts in stratifying patient risk, refining interventional procedures, and addressing sex-specific disparities represent critical strides toward personalized cardiology and equitable healthcare. The broader impact of her work is undeniable in shaping the future landscape of cardiovascular medicine.
Subject of Research: Cardiovascular medicine, Interventional cardiology, Personalized risk assessment, Women’s cardiovascular health
Article Title: Dr. Roxana Mehran Awarded the European Society of Cardiology Gold Medal for Transformative Contributions to Cardiovascular Medicine
News Publication Date: August 29, 2025
Web References:
- https://mediasvc.eurekalert.org/Api/v1/Multimedia/4f02774c-7860-4824-909b-af93660b348d/Rendition/low-res/Content/Public
- https://www.mountsinai.org/
- https://www.escardio.org/
References: Not provided in original content
Image Credits: Mount Sinai Health System
Keywords: Cardiology, Cardiovascular disorders, Interventional cardiology, Clinical trials, Personalized medicine, Women’s cardiovascular health, Cardiovascular research, ESC Gold Medal
